[educational] GLP-1-receptor activation across tissues: pancreas (↑ glucose-dependent insulin, ↓ glucagon → blood-sugar control), gut (↓ motility), hypothalamus (appetite → weight loss, the main weight site), immune cells (anti-inflammatory, ↓ hs-CRP), kidney (CKD benefit), endothelium (CVD benefit), brain (dementia-risk association), heart pacing centers (↑ heart rate, a class effect). — Oral GLP-1 review
Peptides acting on it
Evidence
[educational] Benefits plateau (weight loss above subQ semaglutide 7.2 mg / oral 25–50 mg; glycemic and CVD plateau even lower). −14% MACE in meta-analysis, no oral-vs-subQ difference. — Oral GLP-1 review
[educational] Longevity (beyond weight): −12% all-cause mortality (100k-patient meta-analyses), −45% dementia risk, anti-inflammatory, anti-senescence/↑autophagy; low-dose exenatide gave rapamycin-like molecular anti-aging in mice without weight change. — Longevity Top-5
[literature]Cancer-protective signal (counterpoint to angiogenic peptides): ASCO 2026 real-world data (12,112 pts) — GLP-1 RAs reduced metastatic progression in lung/breast/colorectal/liver cancers (breast death risk −45%); a JAMA Network Open breast-cancer cohort (>840k) found lower mortality (HR 0.35 obesity, 0.09 T2D). Observational; RCTs pending. — SOURCE-asco2026-glp1-cancer-progression, SOURCE-glp1-breast-cancer-outcomes
[literature]Prevention/incidence axis (ASCO 2026 Abstract 10506, JCO Oncology Practice): in 94,827 cancer-free women (BMI≥25), GLP-1 RA exposure → lower breast-cancer incidence (matched OR 0.746, P<.0005; ~25–37% lower odds), reportedly weight-loss-independent — extends the signal from outcomes in patients to not getting cancer. Observational. — SOURCE-glp1-breast-cancer-incidence-mcdonald-2026
[literature]Glucagon/GLP-1 dual-agonist Phase 3 (survodutide, SYNCHRONIZE-1, ADA 2026): up to 16.6% weight loss, fat-driven (visceral −34%, liver fat −63%) — the glucagon arm adds hepatic/visceral-fat and energy-expenditure effects on top of GLP-1 appetite suppression, between single-agonist and triple-agonist tiers. — SOURCE-survodutide-synchronize1-phase3-2026
[literature]Triple-agonist Phase 3 ceiling: retatrutide (GLP-1 + GIP + glucagon) hit up to 28.3% weight loss in TRIUMPH-1 (2026) — above single/dual-agonist plateaus, evidence the glucagon arm adds energy expenditure on top of GLP-1 appetite suppression. — SOURCE-retatrutide-triumph1-phase3